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Abstract
Background: Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor of intermediate biologic potential.
Because of its rarity and nonspecific radiological and diverse pathological findings, AFH is often clinically
misdiagnosed. However, few clinical reports have described this tumor. As reported herein, we analyzed the clinical
and radiological features and clinical outcomes of AFH.
Methods: We retrospectively reviewed the medical records of seven cases histopathologically diagnosed as AFH.
We examined clinical features, MRI findings, histopathological diagnoses, treatments, and outcomes.
Results: These seven cases comprised five male and two female patients with ages ranging from 8 to 50 years old.
The primary locations included upper extremities in 2, lower extremities in 4, and the inguinal region in one
patient. Of the tumors, 4 occurred in subcutaneous tissues and 3 occurred in deep tissues. No cases were
diagnosed as AFH from MRI and needle biopsy results. All cases were diagnosed histopathologically after excision.
After treatment, 2 patients (29%) had tumor recurrence and metastasis, one of whom died from disease
progression. These 2 aggressive cases involved both EWSR1 and CREB1 gene rearrangements as determined by
FISH. The other patients were alive and well without recurrence or metastasis.
Conclusion: AFH is a rare tumor that is difficult to diagnose. Therefore, it tends to be misdiagnosed and to be
treated inadequately by referring physicians. Surgeons must therefore be mindful of the presence of AFH, learn
about appropriate treatment necessary for this tumor, and conduct careful follow-up because AFH can engender
poor outcomes.
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Background
Angiomatoid fibrous histiocytoma (AFH), a rare soft tissue
neoplasm, was described initially as “angiomatoid malig-
nant fibrous histiocytoma” by Enzinger in 1979 [1]. Today,
the precise line of differentiation remains unknown, but
this entity is no longer regarded as “malignant” because of
its benign microscopic appearance and favorable progno-
sis. In the 2013 World Health Organization (WHO)
classification, this tumor was placed under the category of
“intermediate tumors of uncertain differentiation” as AFH
[2]. AFH often presents as a soft tissue mass in the subcu-
tis or deep dermis in the extremities of children and
young adults, with a median age of 13 years [1, 3, 4].
Clinically and radiologically, it is often difficult to differen-
tiate this tumor from vascular tumors, such as heman-
gioendothelioma and angiosarcoma, or simply organized
hematoma. Although the prognosis of patients with AFH
is not poor, it recurs in up to 15% of cases and metasta-
sizes in fewer than 1% of cases [5, 6]. Because of its rarity,
few reports have described its related clinical and
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radiological findings or treatment outcomes. This report
presents the (i) clinical features, (ii) magnetic resonance
imaging (MRI) findings, (iii) histopathological diagnoses,
and (iv) treatments and outcomes of seven cases of AFH.
Methods
We retrospectively reviewed the medical records of
seven cases histopathologically diagnosed as AFH at two
institutions. All histopathological specimens were exam-
ined by a soft tissue pathologist to confirm the diagnosis
(Figs. 1 and 2). All diagnoses were classified according to
current WHO criteria [2]. All of the patients provided
informed consent to the publication of case information.
In the case of children, who could not give consent, their
parents provided consent on their behalf.
Clinical features related to gender, age, tumor size and
site, and symptoms were obtained (Table 1). Furthermore,
we examined the MRI findings (Table 2), histopathological
diagnoses, treatments, and outcomes (Table 3).
Results
Clinical features
These seven cases were composed of five male and two
female patients with an age range of 8 to 50 years (mean,
26.4 years). The primary locations were upper extremity
in two patients, lower extremity in four patients, and the
inguinal region in one patient. Regarding the tumor
sites, four patients had subcutaneous lesions and three
had deep lesions. Five patients presented with a painless
mass, whereas one presented with a painful mass. Only
one patient (case 5) had no symptoms. However, the
mass had been occasionally noted as an abnormal find-
ing after medical examinations. The average and median
sizes of the tumors were 69 mm and 45 mm (range, 10–
303 mm), respectively (Table 1).
Magnetic resonance imaging
Some groups have reported the MRI features of AFH,
including cystic areas, pseudocapsules, peritumoral
edema, enhancement, and fluid–fluid level [7–13]. On
the basis of these findings, we evaluated the imaging
characteristics of each case (Table 2, Figs. 3, 4 and 5).
Fig. 1 Histopathological studies of AFH. The photomicrographic images show: (a) peritumoral lymphoplasmacytic cuffing mimicking a lymph
node; (b) the growth of spindle cells with storiform distributions; (c) pseudoangiomatous spaces filled with blood, fibrous pseudocapsules, and
hemosiderin deposition; and (d) desmin immunoreactivity. (a) Case 3 and (b)-(d) case 6
Fig. 2 A FISH analysis of AFH. The presence of split red and green
signals indicates the presence of EWSR1 rearrangement (case 6)
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Almost all of the lesions were homogeneously or hetero-
geneously isointense to muscle on T1 WI and heteroge-
neously hyperintense on T2 WI. All cases, excluding
case 7, presented variegated gadolinium-enhanced im-
aging. Additionally, pseudocapsule and multilocular
findings were obtained in five cases and peritumoral
edema was noted in six cases. We confirmed the cystic
area and fluid–fluid level in two cases each. Based on
MRI images, the initial diagnoses were hemangioma/ar-
teriovenous malformation in two cases and hematoma,
synovial sarcoma, and myxofibrosarcoma in one case
each. No case was initially diagnosed as AFH.
Histopathological diagnosis
No needle biopsy confirmed the diagnosis of AFH. Four
of the seven cases were initially misdiagnosed as other
soft tissue tumors (cases 2, 3, 5, and 6): these diagnoses
included myxoid liposarcoma, Ewing’s sarcoma, myxofi-
brosarcoma, and synovial sarcoma. Case 4 was initially
diagnosed as a spindle cell tumor. The diagnoses of
these five cases (cases 2–6) were amended to AFH after
pathological review or additional wide resection. Only
two cases were correctly diagnosed as AFH by initial
excisions (Table 3).
Treatments and outcomes
The treatments and outcomes of AFH are presented in
Table 3. Cases 2, 4, and 5 underwent wide excision in
the first treatment. Case 1 was diagnosed as AFH after
an excisional biopsy. Thereafter, we performed additional
wide excision at our institution. Because cases 3 and 6
were diagnosed as Ewing’s sarcoma and synovial sar-
coma, respectively, at their former institutions, these pa-
tients were administered chemotherapy (case 3,
vincristine, doxorubicin, ifosfamide, and actinomycin-D;
case 6, doxorubicin and ifosfamide) and wide excision.
In case 7, only a marginal resection was performed. For
five patients (cases 1, 2, 4, 5, and 7), no further local re-
currence or distant metastasis was observed on the last
day of follow-up. Case 3 had local recurrence and lymph
node metastases at six months after the operation.
Therefore, we performed wide re-excision and lymph
node dissection. This patient has had no local recur-
rence or metastasis during the two years following the
operation. The case 6 patient developed local recurrence
twice and multiple lung metastases after wide resection.
The patient was administered chemotherapy (gemcita-
bine and docetaxel); unfortunately, this patient died four
years after initial treatment despite the induction of sys-
temic chemotherapy.
Table 1 Clinical features of patients with AFH
Case No. Sex Age (years) Size (mm) Site Symptom
1 F 28 23 thigh, subcutaneous mass
2 M 50 45 finger, subcutaneous mass
3 F 8 10 crus, subcutaneous mass, pain
4 M 21 30 upper arm, subcutaneous mass
5 M 36 45 popliteus, intermuscular no
6 M 34 303 thigh, intramuscular mass
7 M 8 62 groin, intramuscular mass












1 homo, iso to muscle hetero − − + + − + hemangioma,
AVM
2 hetero, iso/hyper to
muscle
hetero − + − − + + NA
3 homo, iso to muscle hetero − − + − + + NA
4 homo, iso to muscle hetero − + + − + + synovial sarcoma
5 homo, iso to muscle hetero − + + − + + myxofibrosarcoma
6 hetero, iso/hyper to
muscle
hetero + + + + + + hemangioma,
AVM
7 hetero, iso/hyper to
muscle
hetero + + − − + NA hematoma
NA not applicable, AVM arteriovenous malformation
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Discussion
Classified as an intermediate tumor using the WHO
classification, AFH rarely metastasizes [2]. It generally
follows an excellent clinical course overall. It frequently
occurs in children and young adults in soft tissues, form-
ing a well-circumscribed subcutaneous nodule on the
extremities, head, neck, and trunk. No well-organized
clinical reports exist for AFH because it is a very rare
soft tissue tumor.
Although patients with AFH typically present with a
subcutaneous soft tissue lump, Costa and Weiss et al.
reported that 18% of tumors invaded deep structures such
as skeletal muscle [3]. In our series, three cases (43%) were
in deep lesions. According to previous reports, pain and
tenderness were rarely encountered in AFH patients [1, 6,
14]. In our series, only one case (case 3) had a painful
mass. In addition, AFH often occurs in children and
young adults [1, 2]. However, three of seven patients ex-
amined in the present study were older than 30 years.
On MRI examination, AFH shows homogeneously
hypointense lesions on the T1 WI and heterogeneously
hyperintense lesions on the T2 WI [12]. The pattern of
Table 3 Histopathological diagnosis, treatments, and outcomes
Case
No








1 NA AFH WE NA −/− CDF 10
2 NA myxoid
liposarcoma
ray amputation + −/− CDF 5
3 Ewing sarcoma NA Chemo +WE +# + / + NED 18
4 spindle cell tumor NA WE + −/− CDF 57
5 myxofibrosarcoma NA WE + −/− CDF 61
6 NA synovial sarcoma Chemo +WE +# + / + DOD 55
7 NA AFH observation NA −/− CDF 40
NB needle biopsy, EB excisional biopsy, ME marginal excision, WE wide excision, CDF continuous disease free, NED no evidence of disease, DOD died of disease,
NA not applicable. #. CREB1 rearrangement was also demonstrated by FISH, using custom CREB1 break-apart probe set (GSP laboratory, Kobe, Japan)
a b
c
Fig. 3 A 28-year-old woman diagnosed with angiomatoid fibrous histiocytoma (case 1): (a) T1-weighted spin echo, (b) T2-weighted spin echo,
and (c) STIR images. A 21 × 23 × 22-mm well-circumscribed, round mass is present in the subcutaneous fat of the posterior right thigh. The lesion
is homogeneously hypointense on T1 WI and presents fluid–fluid level (green arrow) and pseudocapsule (yellow arrow) on T2 WI. STIR shows
peritumoral edema (red arrows)
Saito et al. BMC Musculoskeletal Disorders  (2017) 18:31 Page 4 of 8
gadolinium enhancement is a variegated internal and
nodular peripheral appearance. In addition, some groups
reported that AFH shows cystic areas, pseudocapsules,
hemosiderin, and fluid–fluid levels on MRI [7–13].
Martinez et al. reported the double rim sign and invasive
pattern as novel MRI findings for AFH [15]. The double
rim sign refers to the presence of a rim of high signal in-
tensity (RHS) and an adjacent rim of low signal intensity
(RLS), which can be observed on both T2-weighted and
post-contrast images. The invasive pattern presents as ir-
regular infiltrating peritumoral strings of high signal in-
tensity on T2-weighted and post-contrast images. We
believe that these signs were present in the pseudocap-
sule, peritumoral edema, and enhancement of our series.
However, these two typical views were observed only in
two cases (cases 3 and 5). Consequently, the MRI findings
of AFH are nonspecific. Because of its radiological features
and indolent clinical behavior [14], it is often mistaken for
a benign condition such as a hematoma or hemangioma,
potentially leading to inappropriate treatments. Indeed, in
our series, three cases were misdiagnosed from initial MRI
findings as a hematoma or hemangioma. Consequently,
histopathological examination is extremely important to
reach a definitive diagnosis.
The characteristic histological features of AFH have
been well described [2]. These features include the fol-
lowing: (i) multinodular growth of myoid spindled or




Fig. 4 A 36-year-old man diagnosed with angiomatoid fibrous histiocytoma (case 5): (a) T1-weighted spin echo, (b) T2-weighted spin echo, and (c)
contrast-enhanced MR images. (d) Non-enhanced and (e) enhanced CT images. A 32 × 36 × 45-mm asymptomatic mass is present in the popliteal
lesion of right knee. The lesion is homogeneously isointense on T1 WI and presents with a multilocular area (pink arrow) and pseudocapsule (yellow
arrow) on T2 WI. A contrast-enhanced MR image shows intratumoral and peritumoral (white arrow) enhancement. In addition, an enhanced CT image
shows variegated enhancement
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(ii) pseudoangiomatous spaces filled with blood and sur-
rounded by tumor cells, (iii) a thick fibrous pseudocap-
sule with prominent hemosiderin deposition, and (iv)
peritumoral lymphoplasmacytic cuffing with occasional
germinal center formation. However, AFH can display a
wide morphological spectrum. One or more of the
above-described histological findings might be lacking.
Nevertheless, multinodular growth of myoid spindle
cells is consistent. Devoting attention to this pattern and
cytology is crucial for accurate diagnosis. Unusual mor-
phological features that have been reported in a small
number of AFHs include clear cells, small cells with
scanty cytoplasm resembling Ewing’s sarcoma, and
rhabdomyoblast-like cells [2, 16, 17]. In addition, a myx-
oid variant has been established recently in which the
tumors exhibit reticular growth in a prominent myxoid
background. The diagnosis of myxoid AFH can be par-
ticularly challenging. Differential diagnosis includes
other myxoid tumors such as low-grade fibromyxoid sar-
coma, extraskeletal myxoid chondrosarcoma, and myx-
oid liposarcoma [18]. Although there are no entirely
specific immunohistochemical markers for AFH, ap-
proximately half of the tumors express desmin. Epithelial
membrane antigen expression is also characteristic of
AFHs. In addition, AFHs can be uncommonly positive
for other myoid markers such as smooth muscle actin,
calponin, or, rarely, h-caldesmon, but skeletal muscle
markers such as myogenin or MyoD1 are consistently
negative [19]. In our series, aside from two cases (cases
1 and 7), none were diagnosed correctly as AFH from
the initial biopsies. Cases 2 and 6 were misdiagnosed
even after excision.
Recent reports have noted that molecular analyses are
useful ancillary diagnostic techniques for AFH. These
analyses include fluorescence in situ hybridization
(FISH) to detect the rearrangement of EWSR1 or FUS
and reverse transcription-polymerase chain reaction
(RT-PCR) to elucidate EWSR1-CREB1, EWSR1-ATF1,
or FUS-ATF1 fusion transcripts [16, 17, 20]. Tanas et al.
reported that 76% of assessed AFH were shown by FISH
to harbor EWSR1 rearrangement [20]. Thway et al.
showed that both FISH and RT-PCR are equally reliable
for facilitating an AFH diagnosis because one technique
can identify the cases that the other method misses [21].
The detection of EWSR1 rearrangement by FISH was in-
deed helpful for reaching the correct diagnosis in our
a b
c d
Fig. 5 A 34-year-old man diagnosed with angiomatoid fibrous histiocytoma (case 6): (a) T1-weighted spin echo, (b, c) T2-weighted spin echo,
and (d) contrast-enhanced images. A 163 × 130 × 303-mm painless mass is present in the vastus intermedius of the right thigh. The lesion is
heterogeneously iso-hyperintense on T1 WI and presents with a multilocular area, cystic area (blue arrows), fluid–fluid level (green arrows),
pseudocapsule, and peritumoral edema (red arrows) on T2 WI. A contrast-enhanced image shows partial gadolinium enhancement (white arrows)
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series, including five cases (cases 2–6) to which incorrect
labeling was assigned initially. In addition, CREB1 gene
rearrangement further supported the diagnoses in 2
cases (cases 3 and 6) that showed unexpected aggressive
courses. We believe that molecular methods are some-
times necessary for the diagnosis of AFH.
A summary and comparison of the clinical out-
comes of AFH cases described in earlier reports are
presented in Table 4. Although some groups reported
a favorable prognosis of AFH after treatment [3, 22,
23], Enzinger et al. reported that 63% and 21% of pa-
tients had local recurrence and metastasis, respect-
ively, and that 12% of patients had died of the
disease. In a study by Pettinato et al. [22], the prog-
noses were not good: recurrence occurred in 25% of
cases, metastasis occurred in 5% of cases, and death
occurred in 5% of cases. However, some reports pub-
lished before the establishment of molecular analyses
might have included malignant neoplasms other than
AFH. In our series, five patients remained alive and
well without recurrence or metastasis after resection.
However, two patients (29%) had tumor recurrence
and metastasis, one of whom died from disease pro-
gression. Notably, the diagnosis of AFH in both of
these aggressive cases was confirmed by FISH on a
molecular level for the presence of rearrangements of
both EWSR1 and CREB1. Tamas et al. reported that
the influence of the EWSR1-CREB1 fusion gene on
prognosis was not clear [24]. In the AFH cases in
which the EWSR1-CREB1 fusion gene was detected,
only one recurrence case was reported [16]; there
were no reported deaths. Case 6 may be the first fatal
case in which EWSR1-CREB1 was detected. Th-
erefore, the clinical outcome of our cases was
unexpectedly worse than that of others described in
the literature. Additionally, we administered systemic
chemotherapy in case 6, but it was ineffective. Our
results suggest that AFH patients may follow an un-
fortunate course that can rarely be predicted.
Costa et al. reported that an irregular tumor border as
well as a head and neck location were associated with
local recurrence, and the depth of the tumor was corre-
lated with subsequent local and distant metastasis [3].
Furthermore, they showed that the mitotic activity, ex-
treme pleomorphism, inflammatory response, tumor
size, patient age, and adjuvant therapy were not corre-
lated with the clinical behavior. In other studies, the de-
gree of mitotic activity and atypia showed no correlation
with the risk of recurrence. There have been no reports
showing that genetic factors or immunohistochemical
profiles are related to clinical behavior. In our small
number of cases, we detected no definite correlation be-
tween clinical characteristics and prognosis. Neverthe-
less, we did note several features that might be relevant
in the two cases that showed an aggressive course (cases
3 and 6). Specifically, the primary tumor in case 3 was
the only one in our series that presented as a painful
mass, and it exhibited an unusual small round cell
morphology with marked mitotic activity, although its
recurrence showed the classic spindle cell histology of
AFH. Case 6 manifested as a large mass in a deep loca-
tion, and its recurrence demonstrated focally increased
nuclear atypia and pleomorphism compared to the clas-
sic morphology of primary tumors. Interestingly, these
pleomorphic tumor cells harbored an increased (up to
12 copies) number of rearranged EWSR1 genes in con-
trast to a signal copy in non-pleomorphic areas. We sus-
pect that it may be worthwhile to investigate these
features to see if they predict local recurrence and dis-
tant metastasis.
Conclusions
Not only is AFH a rare soft tissue neoplasm, but its
diagnosis is often difficult because of the lack of specific
clinical symptoms and radiological and histopathological
features. In our series, AFH occurred in older patients
and was found in deep lesions. Although it appears that
patients with AFH have excellent prognoses, the rates of
Table 4 Literature review










Enzinger [1] 24 13 (5–25) 15 (63) 5 (21) 3 (12) 36 (12–240)
Costa and Weiss et al. [3] 108 17 (2–70) 11 (12) 4 (4) 1 (1) 63 (5–189)
Pettinato et al. [22] 20 13.4 (3–42) 5 (25) 1 (5) 1 (5) NA
Fanburg et al. [19] 158 20 (2–71) 2 (2) 1 (1) 0 6 (12–276)
Hasegawa et al. [23] 4 22.7 (0.5–54) 1 (25) 0 0 11 (84–204)
Chen et al. [16] 8 48 (22–65) 1 (12.5) 0 0 21 (3–78)
Shi et al. [25] 21 26.9 (8–83) 2 (9.5) 0 0 48 (4–148)
Wilk et al. [26] 9 24 (3–67) 0 NA NA 75 (30–132)
Our series 7 26.4 (8–50) 2 (29) 2 (29) 1 (14.3) 35.1 (5–61)
NA not applicable
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local recurrence and metastasis might be higher than
initially expected. Surgeons must therefore be aware of
AFH and include it in clinical, radiological, and histo-
logical differential diagnoses.
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